COGT
Cogent Biosciences, Inc.Company Information
- Company Name
- Cogent Biosciences, Inc.
- CIK
- CIK0001622229
- Category
- Large accelerated filer
- Ticker: Exchange
- COGT: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- COGT
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-07-10
- Last sale
- 2026-08-27
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 10,860,152
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 186,372,374
- Shares outstanding
- 171,005,468
- Ownership
- 108.99%
Earnings Market Reaction
- Filing date
- 2026-08-10
- Price on filing date
- —
- 1-month reaction
- -16.30%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 181 | 241 | 312 | 125 | 128 | 126 | 98 | 97 | 88 | 216 | 53 | 87 | ||||||
| Available For Sale Securities Debt Securities Current | 611 | 625 | 589 | 266 | 110 | 120 | 189 | 238 | 275 | 220 | 212 | 192 | ||||||
| Prepaid Expense And Other Assets Current | 13 | 11 | 10 | 6 | 7 | 7 | 9 | 6 | 7 | 6 | 5 | 7 | ||||||
| Assets Current | 805 | 878 | 910 | 397 | 245 | 253 | 296 | 342 | 370 | 442 | 271 | 286 | ||||||
| Available For Sale Securities Debt Securities Noncurrent | - | - | - | - | - | - | - | 10 | 27 | 0 | 7 | 34 | ||||||
| Operating Lease Right Of Use Asset | 23 | 18 | 18 | 19 | 19 | 20 | 20 | 21 | 21 | 22 | 22 | 22 | ||||||
| Property Plant And Equipment Net | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 7 | 7 | 8 | 8 | 9 | ||||||
| Restricted Cash Noncurrent | 0 | 0 | 0 | 0 | - | - | 0 | - | - | - | 0 | - | ||||||
| Other Assets Noncurrent | 2 | 2 | 3 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Assets | 835 | 903 | 938 | 426 | 275 | 284 | 328 | 384 | 430 | 476 | 313 | 355 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 7 | 14 | 10 | 16 | 17 | 14 | 12 | 15 | 9 | 16 | 11 | 10 | ||||||
| Operating Lease Liability Current | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | ||||||
| Liabilities Current | 59 | 58 | 64 | 62 | 58 | 49 | 56 | 53 | 40 | 37 | 38 | 35 | ||||||
| Long Term Debt Noncurrent | - | - | - | 44 | 44 | - | - | - | - | - | - | - | ||||||
| Convertible Debt Noncurrent | 223 | 223 | 223 | - | - | - | 0 | - | - | - | - | - | ||||||
| Operating Lease Liability Noncurrent | 19 | 14 | 14 | 15 | 15 | 15 | 16 | 16 | 17 | 17 | 17 | 18 | ||||||
| Other Liabilities Noncurrent | 0 | 0 | 0 | 2 | 2 | 0 | 0 | - | - | - | - | - | ||||||
| Liabilities | 302 | 295 | 301 | 123 | 120 | 65 | 72 | 69 | 57 | 54 | 56 | 53 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 1,850 | 1,829 | 1,735 | 1,280 | 1,052 | 1,042 | 1,005 | 995 | 980 | 862 | 801 | 792 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -1 | -0 | 0 | 0 | 0 | 0 | 0 | 1 | -0 | -0 | 0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -1,382 | -1,286 | -1,188 | -1,086 | -1,005 | -931 | -859 | -792 | -721 | -662 | -604 | -549 | ||||||
| Stockholders Equity | 532 | 608 | 636 | 302 | 155 | 219 | 256 | 315 | 373 | 422 | 258 | 303 | ||||||
| Liabilities And Stockholders Equity | 835 | 903 | 938 | 426 | 275 | 284 | 328 | 384 | 430 | 476 | 313 | 355 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 150 | 300 | 150 | ||||||
| Common Stock Shares Issued | 172 | 171 | 161 | 140 | 114 | 114 | 110 | 110 | 109 | 96 | 86 | 86 | ||||||
| Shares Outstanding | 172 | 171 | 161 | 140 | 114 | 114 | 110 | 110 | 109 | 96 | 86 | 86 | ||||||
| Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period | - | - | - | - | - | 0 | - | - | - | - | - | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialCogent Biosciences, Inc. (COGT) — SEC Financial Statements & Analysis
Cogent Biosciences, Inc. (COGT) is a pharmaceutical preparations company, incorporated in DE. Cogent Biosciences, Inc. trades on Nasdaq as: COGT. Cogent Biosciences, Inc. (COGT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-10. Based on that filing, Cogent Biosciences, Inc. carries a market cap of $6.62B, a P/E ratio of -17.55x, a P/B ratio of 12.43x, an enterprise value of $6.66B, and an EV/EBITDA multiple of -17.20x. On profitability, it posts a Return on Equity (ROE) of -109.74%, a Return on Assets (ROA) of -68.00%, and a Return on Invested Capital (ROIC) of -120.53%. Per share, it reports EPS of $-2.21, diluted EPS of $-2.21, free cash flow per share of $-1.81, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 32.77% year-over-year and EPS growth of -11.12% year-over-year. On the balance sheet, it maintains a current ratio of 13.57x, a quick ratio of 13.36x, working capital of $745.52M, a debt-to-equity ratio of 0.57x, a debt ratio of 0.36, an interest coverage ratio of -75.14x, free cash flow of $-309.24M (TTM), and net debt of $41.87M. Figures sourced from SEC EDGAR.
- Market Cap
- $6.62B
- P/E TTM
- -17.55x
- EPS TTM
- $-2.21
- P/B TTM
- 12.43x
- ROE TTM
- -109.74%
- ROA TTM
- -68.00%
- Debt To Equity
- 0.57x
- Free Cash Flow TTM
- $-309.24M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Cogent Biosciences, Inc. in?
Cogent Biosciences, Inc. (COGT) operates in the Pharmaceutical Preparations industry.
What exchange does COGT trade on?
Cogent Biosciences, Inc. (COGT) trades on the Nasdaq.
Where is Cogent Biosciences, Inc. incorporated?
Cogent Biosciences, Inc. is incorporated in DE.
When was Cogent Biosciences, Inc. (COGT)'s most recent SEC filing?
Cogent Biosciences, Inc. (COGT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-10.
What is COGT's market cap?
Cogent Biosciences, Inc. (COGT) has a market capitalization of $6.62B as of 2026-06-30.
What is COGT's EPS (earnings per share)?
Cogent Biosciences, Inc. (COGT)'s trailing twelve month EPS is $-2.21 as of 2026-06-30.
What is COGT's ROE (return on equity)?
Cogent Biosciences, Inc. (COGT)'s trailing twelve month Return on Equity (ROE) is -109.74% as of 2026-06-30.
What is COGT's ROA (return on assets)?
Cogent Biosciences, Inc. (COGT)'s trailing twelve month Return on Assets (ROA) is -68.00% as of 2026-06-30.
What is COGT's ROIC (return on invested capital)?
Cogent Biosciences, Inc. (COGT)'s trailing twelve month Return on Invested Capital (ROIC) is -120.53% as of 2026-06-30.
What is COGT's EV/EBITDA?
Cogent Biosciences, Inc. (COGT)'s trailing twelve month EV/EBITDA is -17.20x as of 2026-06-30.